Monday, December 19, 2022

Semaglutide for weight loss at NovaGenix


Semaglutide for weight loss at NovaGenix in Jupiter, Florida.



In June 2021, the US food and drug administration approved Semaglutide injections 2.4 mg once weekly for the management of Obesity.   

This is the first time since 2014 that the FDA has approved a weight loss medication for chronic weight management in adults with obesity or overweight with at least one weight related condition like high blood pressure type two diabetes or high cholesterol. to be used in conjunction with a reduced calorie diet and increased exercise, this under the skin injection is indicated for patients with a BMI of 27 or greater with at least one weight related element, or a BMI of 30 or greater. 

approximately 70% of adult Americans are obese or overweight. This is a serious health risk and is associated with some of the leading causes of death in the United States with heart, disease, diabetes, and stroke, all linked to being obese, as well as several types of cancer.  not to mention the physical issues that arise from being obese, such as back and knee pain as well as emotional issues associated with body image, losing 5 to 10% of body weight has been associated with reducing the risk of cardiovascular disease in adult patients who are overweight and/or obese. 

Semaglutide works in patients by mimicking a hormone known as glucagon like peptide-1. GLP-1 targets areas in the brain which control the regulation of appetite and food intake. 

Through the gradual increase dosing of semaglutide, side effects can be mitigated. 

The safety and effectiveness of semaglutide has been studied in for separate trials, which were randomized, double blind, placebo controlled  , randomized, withdraw trial, in which patients receiving Semaglutide would either continue with treatment or switched to a placebo. 

In the trials, the average age of the patient starting Semaglutide was 46 years and 74% of the patients were female. The average body weight was 231 pounds with an average BMI of 38. Patients who receive Semaglutide lost an average of 12.4% of their initial body weight.  


Obesity in the United States is an epidemic , and for patients who need help losing weight, Semaglutide can be a game changer. Losing weight is hard and for many patients, the struggle to begin the weight loss journey seems overwhelming. At NovaGenix we have over 20 years experience in helping patients not just lose weight, but improve their overall health.

With online consultations available, we make getting started easy. Are experiencing licensed physician will be able to guide you through the process, and for patients who qualify, medication can be delivered straight to your door, making NovaGenix affordable, effective and convenient.  

Call or text us at 561-277-8260 to learn more and visit us online at www.novagenix.org to see how we can help get you started to looking, living and feeling your best. 


https://www.novagenix.org/weight-loss/semaglutide-for-weight-loss